QTc prolongation with bedaquiline treatment for drug-resistant pulmonary TB in a programmatic setting

Int J Tuberc Lung Dis. 2023 Apr 1;27(4):329-331. doi: 10.5588/ijtld.22.0406.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antitubercular Agents / adverse effects
  • Diarylquinolines / adverse effects
  • Humans
  • Long QT Syndrome* / chemically induced
  • Tuberculosis, Multidrug-Resistant* / drug therapy
  • Tuberculosis, Pulmonary* / drug therapy

Substances

  • bedaquiline
  • Diarylquinolines
  • Antitubercular Agents